These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11322738)

  • 21. Benefits exceed risks of newer antidepressant medications in youth--maybe.
    March JS; Vitiello B
    Clin Pharmacol Ther; 2009 Oct; 86(4):355-7. PubMed ID: 19763113
    [No Abstract]   [Full Text] [Related]  

  • 22. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors.
    Wilens TE; Biederman J; Kwon A; Chase R; Greenberg L; Mick E; Spencer TJ
    J Child Adolesc Psychopharmacol; 2003; 13(2):143-52. PubMed ID: 12886909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
    Spigset O; Adielsson G
    Int Clin Psychopharmacol; 1997 Jan; 12(1):61-3. PubMed ID: 9179637
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of ribavirin, in combination with interferon in patients with hepatitis C, on the bleeding risk associated with selective serotonin reuptake inhibitors.
    Honda T; Katano Y; Toyoda H; Hayashi K; Ishigami M; Nakano I; Goto H; Yamamoto K; Takamatsu J
    J Clin Psychiatry; 2008 Apr; 69(4):679-80. PubMed ID: 18507491
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.
    Thomas KL; Ellingrod VL
    Pharmacotherapy; 2009 Jul; 29(7):822-31. PubMed ID: 19558256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents.
    Sun JW; Hernández-Díaz S; Haneuse S; Bourgeois FT; Vine SM; Olfson M; Bateman BT; Huybrechts KF
    JAMA Psychiatry; 2021 Jan; 78(1):91-100. PubMed ID: 32876659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy for the brain and gut.
    Szigethy E
    J Psychiatr Pract; 2005 Jan; 11(1):51-3. PubMed ID: 15650622
    [No Abstract]   [Full Text] [Related]  

  • 28. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience.
    DeVane CL; Sallee FR
    J Clin Psychiatry; 1996 Feb; 57(2):55-66. PubMed ID: 8591970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introduction. Optimizing clinical use of SSRIs: theory and practice.
    Glassman AH
    J Clin Psychiatry; 1998; 59 Suppl 15():3. PubMed ID: 9786304
    [No Abstract]   [Full Text] [Related]  

  • 30. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality.
    Stephansson O; Kieler H; Haglund B; Artama M; Engeland A; Furu K; Gissler M; Nørgaard M; Nielsen RB; Zoega H; Valdimarsdóttir U
    JAMA; 2013 Jan; 309(1):48-54. PubMed ID: 23280224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SSRI prescription rates after a terrorist attack.
    DiMaggio C; Galea S; Madrid P
    Psychiatr Serv; 2006 Nov; 57(11):1656-7. PubMed ID: 17085620
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
    Laine K; Heikkinen T; Ekblad U; Kero P
    Arch Gen Psychiatry; 2003 Jul; 60(7):720-6. PubMed ID: 12860776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus.
    Mulder EJ; Ververs FF; de Heus R; Visser GH
    Neuropsychopharmacology; 2011 Sep; 36(10):1961-71. PubMed ID: 21525859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel psychotropic medications in children: new toxicities to master.
    Jacobs ES; Dickstein DP; Liebelt EL
    Pediatr Emerg Care; 2001 Jun; 17(3):226-31. PubMed ID: 11437154
    [No Abstract]   [Full Text] [Related]  

  • 35. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction.
    Dubovsky SL; Thomas M
    J Psychosom Res; 1995 May; 39(4):429-44. PubMed ID: 7562673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective serotonin reuptake inhibitors and discontinuation symptoms.
    Sher L
    J Psychiatry Neurosci; 2001 Mar; 26(2):152. PubMed ID: 11291532
    [No Abstract]   [Full Text] [Related]  

  • 37. Are there guidelines for the responsible prescription of benzodiazepines?
    el-Guebaly N; Sareen J; Stein MB
    Can J Psychiatry; 2010 Nov; 55(11):709-14. PubMed ID: 21070698
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI).
    Baumann P
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():13-20. PubMed ID: 1431018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of selective serotonin reuptake inhibitors in pregnancy.
    De las Cuevas C; Sanz EJ
    Curr Drug Saf; 2006 Jan; 1(1):17-24. PubMed ID: 18690911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
    Lam D; Gorman DA; Patten S; Pringsheim T
    Paediatr Drugs; 2013 Aug; 15(4):319-27. PubMed ID: 23529865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.